Technical Data Sheet

InVivoSIM anti-human CGRPR (Erenumab biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIM0103**
Clone:	**Erenumab**
Isotype:	Human IgG2, λ
Recommended Isotype Control(s):	RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Immunogen:	Human CGRPR
Reported Applications:	*in vivo* functional assays *in vitro* functional assays ELISA Flow cytometry
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/µg) Determined by LAL assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 µm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
Aggregation:	<5% Determined by SEC
RRID:	
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This Erenumab biosimilar antibody uses the same variable regions as the therapeutic antibody Erenumab, making it ideal for research use. Erenumab is a fully human IgG2 monoclonal antibody that specifically targets the calcitonin gene-related peptide receptor (CGRPR), a heterodimeric complex composed of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). The CGRPR is expressed on vascular smooth muscle cells, sensory neurons, and components of the trigeminovascular system, where CGRP signaling drives vasodilation, neurogenic inflammation, and pain transmission associated with migraine pathophysiology. By binding the CGRPR, Erenumab prevents ligand engagement

and downstream signaling, thereby inhibiting CGRP-mediated neurovascular activation. This Erenumab biosimilar is well suited for studying CGRPR biology, neurovascular signaling, pain mechanisms, and for benchmarking therapeutic receptor blockade in pre-clinical experimental systems.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/sim0103?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2026 Bio X Cell, LLC